BioTelemetry, Inc. Elects Laura Dietch and Tiffany Olson to its Board of Directors
February 28 2019 - 8:30AM
BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care, announced today
the election of Laura Dietch and Tiffany Olson to BioTelemetry’s
Board of Directors.
Ms. Dietch has more than twenty-five years of
experience in the medical device industry as a Chief Executive
Officer, company co-founder, director, fundraiser, inventor, and
mentor. She is currently the President and Chief Executive Officer
of BioTrace Medical, Inc., a commercial stage cardiovascular
medical device company, which she co-founded and has led from
inception. Ms. Dietch has gained extensive executive and operating
experience in both private and public companies, having been a
member of the senior management team in several start-up and
Fortune 500 companies, including Progressive Angioplasty Systems,
LuMend and Medtronic. Ms. Dietch is also an active angel investor
as well as a past director and current member of Life Science
Angels and has sat on that group’s Medical Devices Committee for
the past ten years.
Ms. Dietch received her bachelor’s degree in
biochemistry from the University of Massachusetts at Amherst and a
master’s degree in Health and Medical Sciences, Human Genetics, and
a Master of Business Administration from the University of
California at Berkeley.
Ms. Olson is currently the president of Nuclear
& Precision Health Solutions at Cardinal Health, which
develops, manufactures, compounds, dispenses and delivers over ten
million, time-critical, patient specific doses annually. Prior to
Cardinal Health, Ms. Olson was President of NaviMed, a company
focused on personalizing medicine through innovative diagnostics.
She also worked for Eli Lilly and Company, where she was tasked
with leading the effort to formulate the strategy to create and
commercialize diagnostics and companion diagnostics. Ms. Olson also
worked for Roche Diagnostics for many years, where she attained the
position of President and Chief Executive Officer of Roche
Diagnostics Corporation. She was the first woman to receive the
Life Science Alley Luminary Award, recognizing her “rich career in
medical diagnostics…exceptional reputation as a leader and her
vision to drive both innovation and value for personalized
medicine.” In 2013, she received the “Woman of Wellness Award” for
her extraordinary contributions through her volunteer work in
oncology.
Ms. Olson received her bachelor’s degree in
business from the University of Minnesota and a master’s degree
from St. Thomas University in Minnesota.
Joseph Capper, President and Chief Executive
Officer of BioTelemetry, commented, “We could not be happier to
welcome, not one, but two, exceptional industry leaders to the
Board. Laura’s entrepreneurial and angel investing experience will
provide the Board with valuable insight as we examine potential
investments. Tiffany’s extensive management experience in medical
diagnostics will provide the Board with a valuable operations
perspective. Laura and Tiffany are joining our diverse and talented
Board at an exciting time in BioTelemetry’s history. I look forward
to collaborating with them as we continue to shape BioTelemetry’s
strategy.”
About BioTelemetry
BioTelemetry, Inc. is the leading remote medical technology
company focused on delivery of health information to improve
quality of life and reduce cost of care. We provide remote cardiac
monitoring, remote blood glucose monitoring, centralized core lab
services for clinical trials and original equipment manufacturing
that serves both healthcare and clinical research customers. More
information can be found at www.gobio.com.
Contact:
BioTelemetry, Inc.Heather C. GetzInvestor RelationsExecutive Vice
President, Chief Financial
Officer800-908-7103investorrelations@biotelinc.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From May 2024 to Jun 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2023 to Jun 2024